University of Fribourg

Biognosys presents advancements in plasma proteomics, DIA proteomics, and targeted proteomics at the HUPO World Congress, including the P2 Plasma Enrichment System, Spectronaut 19, and SpectroDive 12, highlighting their comprehensive solutions for drug discovery and development.

Aethlon Medical's Hemopurifier®, an immunotherapeutic device for cancer, gains ethics approval in India for a trial in solid tumor patients resistant to anti-PD-1 therapy. The trial aims to assess safety and feasibility, with potential to improve response rates to anti-PD-1 antibodies by removing tumor-produced extracellular vesicles.

Immunotherapy improves long-term survival in advanced melanoma, triple-negative breast cancer, and muscle-invasive bladder cancer, according to studies presented at ESMO 2024. In advanced melanoma, 10-year melanoma-specific survival rate was 96% for patients with no disease progression for at least 3 years. Triple-negative breast cancer patients showed 5-year overall survival rates of 86.6% with immunotherapy plus chemotherapy versus 81.2% with placebo. In muscle-invasive bladder cancer, immunotherapy before surgery significantly improved event-free and overall survival. Challenges remain in understanding and overcoming resistance to immunotherapy.

Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to advance cancer immunotherapies and precision medicine, with a focus on personalized therapeutic cancer vaccine TG4050.